Fig. 4

MErT is enriched in castrate-resistant prostate cancer (CRPC). a Unsupervised hierarchical clustering of 28 benign, 59 localised prostate cancer and 33 metastatic CRPC samples based on the expression of the MErT gene expression signature (MErT GES). Patient samples and expression data from the Grasso cohort [23] (GSE35988). MErT-DN / MErT-UP refers to downregulated / upregulated genes within the MErT GES. Heatmap color refers to normalised z-score. b Principal component analysis plot of the expression of the MErT GES in benign, localised PCa and mCRPC samples from the same cohort [23]. c Adjusted Rand Index of the MErT GES expression in benign vs localised PCa samples, benign vs mCRPC samples, and localised PCa vs mCRPC samples [23]. d Scatter plots showing the MErT GES score in samples of localised and metastatic PCa: di; Grasso cohort [23]; and dii; Taylor cohort [25]; (MSKCC; GSE21034). Error bars indicate SEM. **** p < 0.0001; unpaired t-test. e Enrichment scores of the EMT GES and MErT GES in LNCaP xenografts during PCa progression. Serum levels of prostate-specific antigen (PSA) are also shown